On September 4, 2025 Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, reported that Cofounder and Chief Operating Officer, Travis Whitfill PhD MPH, will deliver a virtual presentation at the H.C. Wainwright 27th Annual Global Investment Conference, which is being held September 8-10, 2025, in New York City (Press release, Azitra, SEP 4, 2025, View Source [SID1234655757]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In the prerecorded presentation, Mr. Whitfill will highlight recent updates and progress with Azitra’s pipeline including the announcement of promising safety results for its Phase 1b clinical trial of the ATR-12 program in Netherton syndrome. The Company also recently announced that the first patient has been dosed in the Phase 1/2 clinical trial of the ATR-04 program in EGFR inhibitor ("EGFRi")-associated dermal toxicity in adults. The design for the ATR-04 trial was presented at the 2025 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting.
Details of the presentation are as follows:
Event:
H.C. Wainwright 27th Annual Global Investment Conference
Date:
September 8-10, 2025
Virtual Presentation:
7:00 AM, ET, September 8, 2025
Presenter:
Travis Whitfill Ph.D., MPH, Cofounder and Chief Operating Officer
Webcast Link:
During the conference, Dr. Whitfill will conduct one-on-one meetings with registered investors and potential partners, showcasing the company’s business and clinical development strategy, recent corporate achievements, and anticipated milestones.